Latest Manufacturing Efficiency News

Nova Eye Medical reported a 23% rise in quarterly sales to US$5.8 million, driven by strong US growth and initial Chinese sales. EBITDA loss narrowed significantly, with positive operational EBITDA recorded.

IDT Australia is poised for its strongest FY26 finish since its transformation began, forecasting a dramatic narrowing of EBITDA losses and revenue growth driven by strategic partnerships and operational upgrades.

AdAlta, Oribiotech, and Cell Therapies have inked a Memorandum of Understanding to deploy Oribiotech’s IRO automated cell therapy manufacturing platform in Australia and Asia Pacific, aiming to slash costs and boost production speed for CAR-T therapies.

DGL Group reported a 5.8% revenue decline to $225.2 million in H1 FY26, weighed down by audit qualifications, ERP rollout delays, and one-off impairments. Despite these headwinds, the company cut net debt by $16.4 million and advanced strategic site consolidations and new facility investments.

Nufarm reports a robust first half of FY26 with underlying EBITDA rising 17% and net debt falling by $130 million, while new CEO Rico Christensen initiates a $50 million cost savings program as part of a strategic refresh.

Clover Corporation has reported a robust first half for FY26, with revenue climbing 17% and margins expanding significantly, underpinning a confident revenue forecast for the full year.

Ridley Corporation’s half-year results reveal a dramatic profit jump driven by its acquisition of Incitec Pivot Fertilisers Distribution, alongside a healthy dividend increase and solid segment performances.

Adrad Holdings reported a modest revenue rise and a dip in statutory profit for the half-year ending December 2025, while its Heat Transfer Solutions segment showed robust growth. The company declared a fully franked interim dividend, reflecting confidence amid ongoing restructuring.

Reliance Worldwide Corporation reported a 4.6% revenue decline and a 34.9% drop in net profit for H1 FY2026, citing US tariffs and weaker demand in key markets. The company balances challenges with cost savings and a shareholder-friendly capital return strategy.

ResMed Inc. reported robust financial results for Q2 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. The company also navigates ongoing patent litigation while maintaining solid liquidity and shareholder returns.

Synertec Corporation Limited has reported a robust 25% increase in revenue for FY26 Q2 alongside a significant turnaround to positive operating cashflow, underpinned by strong project pipelines and strategic partnerships.

Resmed Inc. posted robust Q2 FY2026 results, with revenue climbing 11% to $1.4 billion and a 16% rise in non-GAAP earnings per share, underpinned by strong global demand and operational efficiencies.